论文部分内容阅读
目的:观察布地奈德福莫特罗粉吸入剂治疗慢性阻塞性肺疾病急性加重期(AECOPD)的临床疗效和安全性。方法:80例AECOPD患者随机分为观察组和对照组各40例,两组均采用常规治疗,观察组加用布地奈德福莫特罗粉吸入剂,比较两组临床疗效、症状明显缓解时间、不良反应。结果:观察组总有效率95.0%,对照组总有效率80.0%,观察组疗效优于对照组(P<0.05),观察组咳嗽、咳痰、气喘症状明显缓解时间较对照组显著缩短(P<0.05);两组均未见明显不良反应。结论:布地奈德福莫特罗粉吸入剂治疗AECOPD疗效确切,安全性好。
Objective: To observe the clinical efficacy and safety of budesonide formoterol powder inhaler in the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods: Eighty patients with AECOPD were randomly divided into observation group (40 cases) and control group (40 cases). Both groups were treated by conventional therapy. The observation group was treated with budesonide formoterol powder inhalation. The clinical curative effect was compared between the two groups. ,Adverse reactions. Results: The total effective rate was 95.0% in the observation group and 80.0% in the control group. The curative effect in the observation group was better than that in the control group (P <0.05). The relieving time of cough, expectoration and asthma in the observation group was significantly shorter than that in the control group <0.05). No obvious adverse reactions were found in both groups. Conclusion: The efficacy and safety of budesonide formoterol powder inhaler in the treatment of AECOPD is good.